PROGENICS PHARMACEUTICALS IN - COM (PGNX)

CUSIP: 743187106

Q1 2020 13F Holders as of 31 Mar 2020

Type / Class
Equity / COM
Total 13F shares
58,363,453
Share change
-4,211,253
Total reported value
$221,804,445
Put/Call ratio
49%
Price per share
$3.80
Number of holders
121
Value change
-$27,707,374
Number of buys
47
Number of sells
59

Quarterly Holders Quick Answers

What is CUSIP 743187106?
CUSIP 743187106 identifies PGNX - PROGENICS PHARMACEUTICALS IN - COM in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Institutional Holders of PROGENICS PHARMACEUTICALS IN - COM (PGNX) as of Q1 2020

As of 31 Mar 2020, PROGENICS PHARMACEUTICALS IN - COM (PGNX) was held by 121 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 58,363,453 shares. The largest 10 holders included BlackRock Inc., FARALLON CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, ALLIANCEBERNSTEIN L.P., NORTHERN TRUST CORP, Tamarack Advisers, LP, and Bank of New York Mellon Corp. This page lists 121 institutional shareholders reporting positions in this security for the Q1 2020 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.